Dear Colleagues,

Despite the development of several treatment options, ovarian cancer remains a major cause of death for women worldwide. Early diagnosis is one of the most important factors that determine survival from ovarian cancer. However, current clinical diagnostic tools have limited efficacy for the early detection of this cancer type, hence there is an urgent need for new diagnostic biomarkers. Advances in knowledge acquired from genomic, metabolomic and proteomic techniques should lead to the discovery of novel biomarkers with clinical utility for the diagnosis, prognostic assessment, and therapeutic evaluation of ovarian cancer. Specific diagnostic biomarkers may therefore have profound diagnostic, prognostic and therapeutic implications for ovarian cancer.

Dr.  Juan Zhou

Guest Editor